Susan L. Mercer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Susan L. Mercer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Christopher W. Cunningham
Department of Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, Wisconsin 53097, United States
3 shared publications Andrew Coop
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA
2 shared publicationsAmber M. Bradley
Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, One University, Park Drive, Nashville, TN 37204, USA
1 shared publicationAndrea L. Devereaux
Department of Pharmaceutical Sciences, School of Pharmacy , Concordia University Wisconsin , Mequon , Wisconsin 53097 , United States
1 shared publicationAndrew D. Rosicky
Department of Pharmaceutical Sciences, Concordia University Wisconsin School of Pharmacy, 12800 North Lake Shore Drive, Mequon, WI 53097, USA
1 shared publicationChristopher E. Barton
Department of Biology, Belmont University, 1900 Belmont Boulevard, Nashville, TN 37212, USA
1 shared publication
Latest Publications
- 1 November 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (22) , 115773
Synthesis and evaluation of etoposide and podophyllotoxin analogs against topoisomerase IIα and HCT-116 cells
- 1 November 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (22) , 115773
Synthesis and evaluation of etoposide and podophyllotoxin analogs against topoisomerase IIα and HCT-116 cells
- 12 June 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 9 (10) , 2428-2437
DARK Classics in Chemical Neuroscience: Fentanyl
Fentanyl rose to prominence as an alternative analgesic to morphine nearly 50 years ago; today, fentanyl has re-emerged as a dangerous recreational substance. The increased potency and analgesic effect of fentanyl are advantageous in the treatment of pain but are also responsible for the rise in unintentional opioid overdose deaths. In response to this crisis, fentanyl, its analogues, and even precursors are under heightened regulatory scrutiny. Despite this controversial history, derivatization of fentanyl has resulted in numerous synthetic analogues that provide valuable insights into opioid receptor binding and signaling events. In this review, the impact of fentanyl on chemical neuroscience is shown through its synthesis and properties, manufacturing, metabolism, pharmacology, approved and off-label indications, adverse effects, and the responsibility it has in the opioid epidemic.
- 12 June 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 9 (10) , 2428-2437
DARK Classics in Chemical Neuroscience: Fentanyl
Fentanyl rose to prominence as an alternative analgesic to morphine nearly 50 years ago; today, fentanyl has re-emerged as a dangerous recreational substance. The increased potency and analgesic effect of fentanyl are advantageous in the treatment of pain but are also responsible for the rise in unintentional opioid overdose deaths. In response to this crisis, fentanyl, its analogues, and even precursors are under heightened regulatory scrutiny. Despite this controversial history, derivatization of fentanyl has resulted in numerous synthetic analogues that provide valuable insights into opioid receptor binding and signaling events. In this review, the impact of fentanyl on chemical neuroscience is shown through its synthesis and properties, manufacturing, metabolism, pharmacology, approved and off-label indications, adverse effects, and the responsibility it has in the opioid epidemic.
- 14 May 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 9 (10) , 2395-2407
DARK Classics in Chemical Neuroscience: Morphine
As the major psychoactive agent in opium and direct precursor for heroin, morphine is a historically critical molecule in chemical neuroscience. A structurally complex phenanthrene alkaloid produced by Papaver somniferum, morphine has fascinated chemists seeking to disentangle pharmacologically beneficial analgesic effects from addiction, tolerance, and dependence liabilities. In this review, we will detail the history of morphine, from the first extraction and isolation by Sertürner in 1804 to the illicit use of morphine and proliferation of opioid use and abuse disorders currently ravaging the United States. Morphine is a molecule of great cultural relevance, as the agent that singlehandedly transformed our understanding of pharmacognosy, receptor dynamics, and substance abuse and dependence disorders.
- 14 May 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 9 (10) , 2395-2407
DARK Classics in Chemical Neuroscience: Morphine
As the major psychoactive agent in opium and direct precursor for heroin, morphine is a historically critical molecule in chemical neuroscience. A structurally complex phenanthrene alkaloid produced by Papaver somniferum, morphine has fascinated chemists seeking to disentangle pharmacologically beneficial analgesic effects from addiction, tolerance, and dependence liabilities. In this review, we will detail the history of morphine, from the first extraction and isolation by Sertürner in 1804 to the illicit use of morphine and proliferation of opioid use and abuse disorders currently ravaging the United States. Morphine is a molecule of great cultural relevance, as the agent that singlehandedly transformed our understanding of pharmacognosy, receptor dynamics, and substance abuse and dependence disorders.
- 1 May 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (3) , 405-414
Drugs of Abuse and Addiction: An integrated approach to teaching
- 1 May 2017
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 9 (3) , 405-414
Drugs of Abuse and Addiction: An integrated approach to teaching
- 1 August 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (15) , 3592-3595
Opioids and efflux transporters. Part 4: Influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues
- 1 August 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (15) , 3592-3595
Opioids and efflux transporters. Part 4: Influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues
- 21 September 2011
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 2 (9) , 484-486
ACS Chemical Neuroscience Molecule Spotlight on Contrave
- 21 September 2011
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 2 (9) , 484-486
ACS Chemical Neuroscience Molecule Spotlight on Contrave
- 1 May 2011
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 11 (9) , 1157-1164
Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Chronic clinical pain remains poorly treated. Despite attempts to develop novel analgesic agents, opioids remain the standard analgesics of choice in the clinical management of chronic and severe pain. However, mu opioid analgesics have undesired side effects including, but not limited to, respiratory depression, physical dependence and tolerance. A growing body of evidence suggests that P-glycoprotein (P-gp), an efflux transporter, may contribute a systems-level approach to the development of opioid tolerance. Herein, we describe current in vitro and in vivo methodology available to analyze interactions between opioids and P-gp and critically analyze P-gp data associated with six commonly used mu opioids to include morphine, methadone, loperamide, meperidine, oxycodone, and fentanyl. Recent studies focused on the development of opioids lacking P-gp substrate activity are explored, concentrating on structure-activity relationships to develop an optimal opioid analgesic lacking this systems-level contribution to tolerance development. Continued work in this area will potentially allow for delineation of the mechanism responsible for opioid-related P-gp up-regulation and provide further support for evidence based medicine supporting clinical opioid rotation.
- 1 May 2011
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 11 (9) , 1157-1164
Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Chronic clinical pain remains poorly treated. Despite attempts to develop novel analgesic agents, opioids remain the standard analgesics of choice in the clinical management of chronic and severe pain. However, mu opioid analgesics have undesired side effects including, but not limited to, respiratory depression, physical dependence and tolerance. A growing body of evidence suggests that P-glycoprotein (P-gp), an efflux transporter, may contribute a systems-level approach to the development of opioid tolerance. Herein, we describe current in vitro and in vivo methodology available to analyze interactions between opioids and P-gp and critically analyze P-gp data associated with six commonly used mu opioids to include morphine, methadone, loperamide, meperidine, oxycodone, and fentanyl. Recent studies focused on the development of opioids lacking P-gp substrate activity are explored, concentrating on structure-activity relationships to develop an optimal opioid analgesic lacking this systems-level contribution to tolerance development. Continued work in this area will potentially allow for delineation of the mechanism responsible for opioid-related P-gp up-regulation and provide further support for evidence based medicine supporting clinical opioid rotation.
- 20 April 2011
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 2 (4) , 183-184
ACS Chemical Neuroscience Molecule Spotlight on Qnexa
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission.
- 20 April 2011
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 2 (4) , 183-184
ACS Chemical Neuroscience Molecule Spotlight on Qnexa
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical trials for the treatment of obesity. Vivus, Inc. has demonstrated efficacy of their product and are currently addressing FDA safety concerns with the possibility of a New Drug Application (NDA) resubmission.